Figure 3
From: ADAM12 is an independent predictor of poor prognosis in liver cancer
Survival outcomes and multivariate analysis. (A) The effect of ADAM12 expression on overall survival in liver cancer patients in the TCGA cohort. The median score was used to categorize patients into high expression and low expression groups. OS analysis of liver cancer patients with high and low ADAM12 expression for (B) 12 months (1 year), (C) 36 months (3 years), and (D) 60 months (5 years). (E) Forest map showing the results of the multivariate analysis. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate significance.
